Brokerages expect Horizon Pharma PLC (NASDAQ:HZNP) to announce $267.58 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Horizon Pharma’s earnings. The highest sales estimate is $268.91 million and the lowest is $266.25 million. Horizon Pharma posted sales of $310.35 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 13.8%. The business is expected to announce its next quarterly earnings results on Monday, February 26th.

According to Zacks, analysts expect that Horizon Pharma will report full year sales of $267.58 million for the current fiscal year. For the next fiscal year, analysts forecast that the business will report sales of $1.13 billion per share, with estimates ranging from $1.12 billion to $1.15 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Horizon Pharma.

Horizon Pharma (NASDAQ:HZNP) last issued its earnings results on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.04. Horizon Pharma had a negative net margin of 45.28% and a positive return on equity of 20.22%. The company had revenue of $271.60 million for the quarter, compared to analyst estimates of $259.74 million. During the same period in the prior year, the business posted $0.70 earnings per share. The firm’s revenue for the quarter was up 30.1% compared to the same quarter last year.

HZNP has been the topic of several recent research reports. Piper Jaffray Companies set a $18.00 price target on shares of Horizon Pharma and gave the company a “buy” rating in a report on Sunday, September 10th. Mizuho reaffirmed a “hold” rating and issued a $12.00 price target (up previously from $9.00) on shares of Horizon Pharma in a report on Monday, August 28th. Zacks Investment Research downgraded shares of Horizon Pharma from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. ValuEngine downgraded shares of Horizon Pharma from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Jefferies Group upped their price objective on shares of Horizon Pharma from $16.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, November 7th. One analyst has rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the stock. Horizon Pharma currently has an average rating of “Buy” and a consensus target price of $18.75.

Shares of Horizon Pharma (HZNP) opened at $14.33 on Friday. Horizon Pharma has a fifty-two week low of $9.45 and a fifty-two week high of $20.35. The stock has a market cap of $2,356.68, a PE ratio of 10.42, a price-to-earnings-growth ratio of 1.22 and a beta of 1.31. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.64 and a quick ratio of 1.52.

Several institutional investors have recently added to or reduced their stakes in the company. California Public Employees Retirement System increased its position in shares of Horizon Pharma by 3.4% in the third quarter. California Public Employees Retirement System now owns 325,085 shares of the biopharmaceutical company’s stock worth $4,122,000 after acquiring an additional 10,585 shares in the last quarter. Cubist Systematic Strategies LLC grew its holdings in Horizon Pharma by 878.1% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 49,493 shares of the biopharmaceutical company’s stock valued at $628,000 after purchasing an additional 44,433 shares in the last quarter. Cornerstone Capital Management Holdings LLC. grew its holdings in Horizon Pharma by 160.3% during the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 176,200 shares of the biopharmaceutical company’s stock valued at $2,233,000 after purchasing an additional 108,500 shares in the last quarter. Segall Bryant & Hamill LLC grew its holdings in Horizon Pharma by 8.9% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 643,928 shares of the biopharmaceutical company’s stock valued at $8,165,000 after purchasing an additional 52,454 shares in the last quarter. Finally, Advantage Investment Management LLC grew its holdings in Horizon Pharma by 164.8% during the 3rd quarter. Advantage Investment Management LLC now owns 7,874 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 4,900 shares in the last quarter. 86.59% of the stock is owned by institutional investors.

WARNING: “$267.58 Million in Sales Expected for Horizon Pharma PLC (HZNP) This Quarter” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/03/267-58-million-in-sales-expected-for-horizon-pharma-plc-hznp-this-quarter-2.html.

Horizon Pharma Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Get a free copy of the Zacks research report on Horizon Pharma (HZNP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.